Needham & Company Stays Sidelined on Acadia Pharmaceuticals (ACAD), 'No Major Surprises in AdCom Docs; FDA Concerns Stand'
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Hold rating on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments "FDA released briefing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
